These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7114805)

  • 1. In vitro selection of tumor cells obtained from patients with ovarian carcinoma. A cytogenetic study.
    Bartnitzke S; Bullerdiek J; Wuestenberg B; Schloot W
    Anticancer Res; 1982; 2(1-2):75-8. PubMed ID: 7114805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic observations on two ovarian carcinomas with double minutes, one with a 6q- marker chromosome.
    Bullerdiek J; Bartnitzke S; Kahrs E; Schloot W
    Cytobios; 1985; 42(165):15-24. PubMed ID: 3858061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal analysis in malignant ovarian tumors.
    Sonwalker AA; Grover S
    Am J Obstet Gynecol; 1974 Apr; 118(7):961-5. PubMed ID: 4361960
    [No Abstract]   [Full Text] [Related]  

  • 4. Recurrent cytogenetic aberrations in human ovarian carcinomas.
    Kiechle-Schwarz M; Bauknecht T; Schmidt J; Walz L; Pfleiderer A
    Cancer Detect Prev; 1995; 19(3):234-43. PubMed ID: 7750111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection toward diploid cells in prostatic carcinoma derived cell cultures.
    Ketter R; Zwergel T; Romanakis K; Unteregger G; Ziegler M; Zang KD; Wullich B
    Prostate; 1996 Jun; 28(6):364-71. PubMed ID: 8650073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a human ovarian carcinoma cell line: UCI 101.
    Fuchtner C; Emma DA; Manetta A; Gamboa G; Bernstein R; Liao SY
    Gynecol Oncol; 1993 Feb; 48(2):203-9. PubMed ID: 8428692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel technique for the enrichment of primary ovarian cancer cells.
    Chan JK; Hamilton CA; Anderson EM; Cheung MK; Baker J; Husain A; Teng NN; Kong CS; Negrin RS
    Am J Obstet Gynecol; 2007 Nov; 197(5):507.e1-5. PubMed ID: 17980191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor progression studied by analysis of cellular features of serial ascitic ovarian carcinoma tumors.
    Mackillop WJ; Trent JM; Stewart SS; Buick RN
    Cancer Res; 1983 Feb; 43(2):874-8. PubMed ID: 6848199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential involvement of chromosome 11 as add(11)(p15) in ovarian cancer: is it a common cytogenetic abnormality in cancer?
    Panani AD
    Cancer Lett; 2007 Dec; 258(2):262-7. PubMed ID: 17945413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map.
    Micci F; Weimer J; Haugom L; Skotheim RI; Grunewald R; Abeler VM; Silins I; Lothe RA; Trope CG; Arnold N; Heim S
    Genes Chromosomes Cancer; 2009 Feb; 48(2):184-93. PubMed ID: 18973136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chromosome anomalies in malignant tumors].
    Terashima Y; Kinoshita H; Nakajima J; Ishida R; Kushimoto T
    Sanfujinka No Jissai; 1969 Sep; 18(9):809-20. PubMed ID: 5394764
    [No Abstract]   [Full Text] [Related]  

  • 12. Cytogenetic and molecular cytogenetic characterization of the stable ovarian carcinoma cell line (OvBH-1).
    Schlade-Bartusiak K; Sasiadek MM; Bar JK; Urbschat S; Blin N; Montenarh M; Harłozińska-Szmyrka A
    Cancer Genet Cytogenet; 2006 Jan; 164(1):10-5. PubMed ID: 16364757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific cytogenetic changes in ovarian cancer involving chromosomes 6 and 14.
    Wake N; Hreshchyshyn MM; Piver SM; Matsui S; Sandberg AA
    Cancer Res; 1980 Dec; 40(12):4512-8. PubMed ID: 7438085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Flow fluorescence-photometry in ovarian carcinomas with and without effusion].
    Krug H; Ebeling K
    Zentralbl Gynakol; 1976; 98(7):410-7. PubMed ID: 134608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of chromosome examination in effusions from cancer patients.
    Olinici CD; Giurgiuman M; Galatâr N; Lazarov P; Mârza V
    Arch Geschwulstforsch; 1976; 46(2):129-39. PubMed ID: 962504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chromosome composition of ascitic and pleural fluid cells in cancer].
    Genes IS
    Vopr Onkol; 1970; 16(9):39-45. PubMed ID: 5486440
    [No Abstract]   [Full Text] [Related]  

  • 18. Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases.
    Taetle R; Aickin M; Yang JM; Panda L; Emerson J; Roe D; Adair L; Thompson F; Liu Y; Wisner L; Davis JR; Trent J; Alberts DS
    Genes Chromosomes Cancer; 1999 Jul; 25(3):290-300. PubMed ID: 10379876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytologic and biologic studies of endometrioid carcinoma of the ovary.
    Nagai S; Nozawa S; Kurihara S; Mukai M
    Acta Cytol; 1983; 27(6):676-82. PubMed ID: 6580802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial ovarian carcinoma.
    Borrie PM; Thomson JD
    N Z Med J; 1982 Mar; 95(703):147-8. PubMed ID: 6952125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.